• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC

    8/14/24 12:53:53 PM ET
    $CBAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CBAY alert in real time by email
    New Drug Application (NDA): 217899
    Company: CYMABAY THERAPEUTICS INC
    • Email

    Products on NDA 217899

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    LIVDELZI SELADELPAR 10MG CAPSULE;ORAL Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 217899

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    08/14/2024 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf

    Labels for NDA 217899

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    08/14/2024 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf
    Get the next $CBAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBAY

    DatePrice TargetRatingAnalyst
    2/13/2024Outperform → Mkt Perform
    Raymond James
    8/14/2023$18.00Buy
    UBS
    8/11/2023$20.00Buy
    Guggenheim
    4/5/2023Outperform
    William Blair
    3/9/2023$15.00Buy
    BTIG Research
    4/11/2022$9.00Overweight
    Cantor Fitzgerald
    11/11/2021$12.00 → $14.00Strong Buy
    Raymond James
    8/3/2021$13.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CBAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC

      Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity

      8/14/24 12:53:53 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Loewy Caroline M

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:09:21 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mcwherter Charles returned 46,938 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:06:11 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lefebvre Eric

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:05:48 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CymaBay Therapeutics downgraded by Raymond James

      Raymond James downgraded CymaBay Therapeutics from Outperform to Mkt Perform

      2/13/24 6:29:47 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on CymaBay Therapeutics with a new price target

      UBS initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $18.00

      8/14/23 7:12:38 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on CymaBay Therapeutics with a new price target

      Guggenheim initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $20.00

      8/11/23 7:12:36 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

      NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as President of Research and Development. "We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer. Chuck joined CymaBay in 2007 and has served as Chief Scientific Officer since 2013. In this role he has been instrumental in the development of seladelpar. Chuck's extensive experience in the pharmaceutical industry

      11/1/22 8:01:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors

      NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors. "We are excited to be welcoming Éric to the Board. Éric's extensive experience in the pharmaceutical industry as an executive focused on clinical development, medical affairs, business development and life-cycle strategy and more than 10 years of experience developing drugs in liver disease indications make him a perfect addition to our Board. We look forward to Éric helping guide us thr

      3/17/22 4:25:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    SEC Filings

    See more
    • SEC Form 15-12G filed by CymaBay Therapeutics Inc.

      15-12G - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      4/1/24 6:04:16 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:07 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:28 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care